GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Total Receivables

Benevolent AI (Benevolent AI) Total Receivables : $3.29 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Total Receivables?

Benevolent AI's Total Receivables for the quarter that ended in Dec. 2023 was $3.29 Mil.


Benevolent AI Total Receivables Historical Data

The historical data trend for Benevolent AI's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Total Receivables Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial 15.55 14.90 0.58 1.08 3.29

Benevolent AI Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only 0.58 8.16 1.08 9.99 3.29

Benevolent AI Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Benevolent AI Total Receivables Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Benevolent AI (Benevolent AI) Business Description

Comparable Companies
Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.